Skip to main content
. Author manuscript; available in PMC: 2013 Jan 15.
Published in final edited form as: Bioorg Med Chem. 2011 Jul 7;20(2):607–613. doi: 10.1016/j.bmc.2011.06.039

Figure 2.

Figure 2

Structures of BODIPY-labeled epoxomicin and MV151. BODIPY-labeled epoxomicin selectively targets constitutive proteasome subunits β1, β5 and, to a lesser extent, LMP7, while MV151 covalently modifies all catalytically active proteasome subunits.